Apoptosis and bcl-2 expression in prostate cancer: Significance in clinical outcome after brachytherapy

Journal of Urology

Volumn 165, Issue 6 I, 2001, Pages

  Szostak, M J ^a   Kaur, P ^a   Amin, P ^a   Jacobs, S C ^a   Kyprianou, N ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Brachytherapy; Genes, bcl 2; Prostate; Prostatic neoplasms

Indexed keywords

IODINE 125; PALLADIUM 103; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NICK END LABELING; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION; TREATMENT FAILURE; ADENOCARCINOMA; AGED; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; PROTO ONCOGENE; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; APOPTOSIS; BRACHYTHERAPY; GENES, BCL-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 0034991759     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)66306-9     Document Type: Article

References (36)

1. Local failure and related complications after definitive treatment of carcinoma of the prostate by irradiation or surgery
2. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathologic stage of localized prostate cancer in a multi-institutional update
3. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer
4. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
5. A comparison of different irradiation therapies for prostate cancer
6. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma
7. Complications after prostate brachytherapy in the Medicare population
8. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection
9. 125iodine brachytherapy for localized prostate cancer
10. Transient tyrosine phosphorylation of p34cdc2 is an early event in radiation-induced apoptosis of prostate cancer cells
11. Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin
12. Radiation inactivation of human prostate cells: The role of apoptosis
13. Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy
14. Bcl-2 over- expression delays radiation-induced apoptosis without affecting clonogenic survival of human prostate cancer cells
15. Bcl-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy
16. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14,18) chromosome translocation
17. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
18. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death
19. Bcl-2 and the regulation of programmed cell death
20. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity
21. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis
22. Bcl-2 and bax function independently to regulate cell death
23. Bax suppresses tumorigenesis and stimulates apoptosis in vivo
24. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma
25. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax: Bcl-2 ratio
26. Bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer
27. Consensus statement: Guidelines for PSA following radiation therapy
28. Incidence of apoptosis and cell proliferation in prostate cancer: Relationship with TGF-β1 and bcl-2 expression
29. Radiation biology and treatment options in radiation oncology
30. Bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy
31. The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients
32. Bcl-2 protein: A prognostic factor inversely correlated to p53 in non-small-cell lung cancer
33. Prostate cancer radiation therapy
34. Combined analysis with bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma
35. Role of apoptosis in development of benign prostatic hyperplasia (BPH) and prostate cancer: Clinical significance in diagnosis and treatment
36. Implication of cell kinetic changes during the progression of human prostatic cancer